The number of U.S. retail opioid prescriptions fell by 10.2% in 2017, including a 16.1% decline in high-dose prescriptions, according to a report released today by the IQVIA Institute for Human Data Science. The Centers for Disease Control and Prevention defines high-dose prescriptions as 90 morphine milligram equivalents or more per day. Total MME volume fell by 12%, or 23.3 billion, the largest annual drop in more than 25 years, according to the report. New opioid therapy starts fell 7.8%, while treatment starts for medication-assisted therapies nearly doubled to 82,000 prescriptions per month. The report also includes many other findings about drug spending, including that patients spent $57.8 billion in 2017 in out-of-pocket costs for medicines, including copays, coinsurance, payments during deductible phases of their insurance, or due to lack of insurance coverage.

Related News Articles

Headline
Cigna’s Evernorth division Oct. 27 announced a new, rebate-free pharmacy benefit model, beginning in 2027, that would reduce monthly prescription drug costs by…
Headline
The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released…
Headline
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by…
Headline
The Food and Drug Administration Sept. 10 released draft guidance on non-opioid treatments for treating chronic pain and reducing prescription opioid misuse.…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…